- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Sarah Cannon Research Institute | Strategic Alliance Partners
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. In 2022, SCRI joined with former US Oncology Research to expand clinical trial access across the country. It has conducted more than 750 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. SCRI’s research network brings together more than 1,300 physicians who are actively enrolling patients into clinical trials at more than 250 locations in 24 states across the U.S. Learn more about our research offerings.
Connect with us:
Latest from Sarah Cannon Research Institute
Lack of Concordance Regarding Plasma Testing in Lung Cancer Must Be Overcome
February 16, 2021
Article
Andrew Mckenzie, PhD, discusses the differences between tissue- and plasma-based NGS tests, factors that can lead to a lack of concordance, and important areas of ongoing research.
Dr. Spigel Discusses Advances in Early-Stage Lung Cancer
February 01, 2021
Video
David Spigel, MD, discusses advances in early-stage lung cancer treatment.
Dr. McKenzie on the Rationale for Concurrent Tissue and Liquid Biopsies in Lung Cancer
February 01, 2021
Video
Andrew McKenzie, PhD, discusses the rationale to utilize concurrent tissue- and liquid-based biopsies in lung cancer.
Assessing the Advantages of Adjuvant Targeted Therapy in Lung Cancer
January 25, 2021
Article
David Spigel, MD, discusses the future of adjuvant targeted therapy in lung cancer.
Experts Provide Real-World Advice for Molecular Testing in Gastrointestinal Malignancies
January 25, 2021
Article
Johanna C. Bendell, MD, moderates a peer exchange with fellow experts to discuss differences in germline and somatic BRCA mutations in pancreatic cancer, the role of molecular testing in hepatocellular carcinoma, and treatment options for patients with BRAF-mutant, microsatellite instability–high colorectal cancer.
Immunotherapy Could Restore the Value of Neoadjuvant Therapy in Lung Cancer
January 22, 2021
Article
David Spigel, MD, discusses ongoing research with immunotherapy in early-stage lung cancer.
Dr. Hamilton on the Rationale Behind OP-1250 in HR+ Metastatic Breast Cancer
January 21, 2021
Video
Erika P. Hamilton, MD, discusses the rationale behind examining OP-1250 in patients with hormone receptor (HR)–positive, HER2-negative breast cancer.
Dr. Burris on the Potential for Novel Checkpoint Inhibitor Combinations in Oncology
January 21, 2021
Video
Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the potential of novel combination strategies with checkpoint inhibitors in oncology.
Johnson Assumes Director Post of Lung Cancer Research at Sarah Cannon Research Institute
January 12, 2021
Article
Melissa Johnson, MD, shares her goals for the first 100 days as program director of the Lung Cancer Research at Sarah Cannon Research Institute, the current state of the anti-TIGIT antibody tiragolumab, and the future of lung cancer treatment.
Sarah Cannon Promotes Melissa Johnson to Program Director, Lung Cancer Research
December 18, 2020
Article
December 18, 2020 - Sarah Cannon announced the promotion of Melissa Johnson, MD, to Program Director of Lung Cancer Research.
RET Inhibitor Enters the Therapeutic Ring in Multiple Settings
October 14, 2020
Article
Todd Bauer, MD, discusses how the highly specific nature of selpercatinib leads to greater tolerability than multityrosine kinase inhibitors and its frontline potential.
Dr. Burris on the Exploration of PARP Inhibitors in TNBC
October 08, 2020
Video
Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the exploration of PARP inhibitors in triple-negative breast cancer.
Dr. Hamilton on the Exploration of CDK4/6 Inhibitors in Breast Cancer
October 06, 2020
Video
Erika P. Hamilton, MD, discusses the exploration of CDK4/6 Inhibitors in HER2-positive breast cancer.
Dr. Hamilton on Initial Findings From the LIO-1 Trial in Advanced Metastatic Tumors
October 01, 2020
Video
Erika P. Hamilton, MD, highlights initial findings from the ongoing phase 1b/2 LIO-1 trial in advanced metastatic tumors.
Dr. Bachier on the Potential Benefits of Liso-Cel in DLBCL
September 17, 2020
Video
Carlos R. Bachier, MD, discusses the investigational CAR T-cell therapy lisocabtagene maraleucel in diffuse large B-cell lymphoma.
ASCO 2020 Data Point to New Wave of Immunotherapy Approaches in NSCLC
September 10, 2020
Article
David R. Spigel, MD, discusses the IMpower110, CYPRESS-1, and CANOPY-A trials, and spoke to the potential future outlook of drug development in NSCLC.
Dr. Burris on Recent Advances in TNBC
September 08, 2020
Video
Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses recent advancements made in the field of triple-negative breast cancer.
Dr. Hamilton on the Complex Treatment Algorithm for HER2+ Breast Cancer
September 08, 2020
Video
Erika P. Hamilton, MD, discusses the complex treatment algorithm for HER2-positive breast cancer.
Dr. Flinn on the Design of a Phase 2 Trial of Zanubrutinib in CLL/SLL
August 31, 2020
Video
Ian W. Flinn, MD, PhD, discusses the design of a phase 2 trial evaluating zanubrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Dr. Hamilton on Recent Advances in HER2+ Breast Cancer
August 31, 2020
Video
Erika P. Hamilton, MD, discusses the roles of fam-trastuzumab deruxtecan-nxki and tucatinib in HER2-positive breast cancer.